Bristol-Myers Squibb Company (BMY)

NYQ – Real Time Price. Currency in USD

56.45

+0.78 (1.40%)

At close: May 12, 2026, 4:00 PM EDT

56.43

-0.02 (-0.04%)

After-hours: May 12, 2026, 7:49 PM EDT

12.05.2026

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

Highlights Nominees' Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has sent a letter to stockholders in connection with its upcoming 2026 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to be held on June 9, 2026.

12.05.2026

Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up

U.S. pharmaceutical giant Bristol-Myers Squibb has struck a strategic partnership and licensing deal with major Chinese drugmaker Hengrui Pharmaceuticals, in a deal that could worth more than $15 billion.

12.05.2026

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreements include 13 programs with the potential to address significant unmet patient needs and support long ‑ term growth SHANGHAI and PRINCETON, N.J., May 12, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui") (600276.SH; 01276.HK) and Bristol Myers Squibb ("BMS") today announced the companies have entered into global strategic collaboration and license agreements to advance a portfolio of 13 early stage programs in oncology, hematology and immunology, with the goal of accelerating discovery and development of innovative medicines for the benefit of patients worldwide.

12.05.2026

China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln

China's Jiangsu Hengrui Pharmaceuticals ‌said on Tuesday it has struck global ⁠strategic collaboration and licensing deal with U.S. drugmaker Bristol Myers Squibb to ‌develop ⁠13 early‑stage oncology, hematology and immunology ⁠programmes, with potential milestone ⁠payments of up ⁠to $15.2 billion.

12.05.2026

Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors.

Bristol Myers Squibb has faced patent cliffs in recent years and will face more in the next few years. The company's portfolio of newer drugs, along with its deep pipeline, can help it overcome this headwind.

10.05.2026

Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting

Bristol Myers Squibb NYSE: BMY used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives, while shareholders approved all management proposals and rejected a proposal to require an independent board chair.

08.05.2026

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #POETYK--Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults.

Videos

06.02.2026

Positive

Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade

21.01.2026

Neutral

Final Trade: BMY, IGV, SOXX, GEN, AMZN

20.01.2026

Positive

2 Top Blue-Chip Stocks to Buy and Hold in 2026

23.12.2025

Neutral

Jenny Harrington's top dividend plays for 2026

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
BMY	Cantor Fitzgerald	Neutral	undefined >> $55	April 22nd 2025
BMY	Piper Sandler	Overweight	undefined >> undefined	April 22nd 2025
BMY	Jefferies	Buy	undefined >> $70	December 16th 2024

Press releases

12.05.2026

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

12.05.2026

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

08.05.2026

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #POETYK--Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults.

06.05.2026

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026.

Bristol-Myers Squibb Company (BMY)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Bristol-Myers Squibb Company (BMY)

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln

Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors.

Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting